|
Scoring pAkt expression determined by immunohistochemistry |
|||
| Author/Reference |
Method and cutoff level |
Antibody (company) |
Positive rate, type of cancer, (city) |
|
|
|||
| Stål, et al. [37] |
>10% strong staining in tumor cells |
pAkt-Ser473 (Upstate Biotechnology, Lake Placid, NY, USA) |
27%, breast cancer, (Stockholm, Sweden) |
| Kirkegaard, et al. [36] |
Above median level of histoscore (inter-quartile range) |
pAkt-Ser473 (Biosource International, Camarillo, CA, USA) |
51%, breast cancer, (Glasgow, UK) |
| Tokunaga, et al. [33] |
≥ 10% of cytoplasm staining |
pAkt-Ser473 (Cell Signaling Technology, Inc., Danvers, MA, USA) |
34%, breast cancer, (Fukuoka, Japan) |
| Messersmith, et al. [39] |
Quantify by Automated Cellular Imaging System (ACIS II, Chromavision, Inc). (combination of staining color, density, and darkness) as a continuous variable |
pAkt-Ser473 (Cell Signaling Technology, Inc.) |
High level in tumor, colorectal cancer, (Maryland, USA) |
| Bose, et al. [40] |
Scoring as 0 to 2 according to intensity; 2 (overexpression) means staining more than normal cells |
pAkt-Ser473 (Cell Signaling Technology, Inc.) |
36%, breast cancer, (Los Angeles, CA, USA) |
| Massarelli, et al. [41] |
More than 15% cytoplasm staining |
pAkt-Ser473 (Cell Signaling Technology, Inc.) |
46%, tongue cancer, (Houston, TX, USA) |
| Ogino, et al. [42] |
Tumor cells were scored as negative or positive, using normal epithelial cells and lymphocytes as reference |
pAkt-Ser473 (Cell Signaling Technology, Inc.) |
14%, colorectal cancer, (Boston, MA, USA) |
| Schmitz, et al. [43] |
More than 45% tumor cells staining in nuclei |
pAkt-Ser473 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) |
88%, breast cancer, (Essen, Germany) |
| Our study |
Combination of staining intensity and percentage of tumor cells as pAkt index, according to quartiles of pAkt index |
pAkt-Ser473 (Cell Signaling Technology, Inc.) |
50%, breast cancer, (Los Angeles) |
Wu et al. Breast Cancer Research 2008 10:R3 doi:10.1186/bcr1844 |
|||